Senators on the Judiciary Committee spent their second full day slogging through proposed amendments to the bipartisan immigration overhaul. Tuesday's subject was the method of awarding visas for those wanting to come here to study and work.
In an NPR interview, Attorney General Eric Holder answers questions about the IRS's processing of tax-exemption applications, the Justice Department's subpoenas for reporters' phone records and other hot issues. Holder faces questions on Capitol Hill Wednesday during an oversight hearing.
A Treasury Department Inspector General's report criticizes the IRS for inappropriately flagging some conservative groups for additional scrutiny on their applications for tax-exempt status. President Obama says those responsible must be held accountable.
Tea Party activists are calling for a full investigation, and possibly lawsuits, following revelations that the Internal Revenue Service flagged so-called patriot groups for extra scrutiny in applications for federal tax-exempt status.
Among those claiming unjust and unconstitutional targeting by the IRS is a group called TheTeaParty.net, which bills itself as the largest grass-roots conservative Tea Party organization in the country.
The sudden eruption of second-term scandals in his administration will have many costs for President Obama, but surely the most grievous will be the lost opportunity to transcend the partisan wars of Washington. That aspiration was his fondest dream for his second term, much as it was for his first. Now it seems destined to be dashed once again.
The Senate Judiciary held its second round of debate on changes to the bipartisan immigration bill. Tuesday's focus was visas for workers, including visas for skilled technical work. David Welna talks to Melissa Block.
When it comes to approving new medical treatments, the Food and Drug Administration is balancing the need for patient safety against the urgency of making important new treatments available as quickly as possible.
Some argue the FDA sets the bar too high, requiring a process that takes too much time and money to carry out. They say that can leave patients waiting longer than necessary for promising treatments or lead to drugs not being developed at all.